(News Bulletin 247) – Innate Pharma unveiled this weekend preclinical data concerning a new therapeutic antibody intended for the treatment of B-cell non-Hodgkin’s lymphoma.
In preclinical studies, the compound, dubbed IPH6501, induced NK cell proliferation and strong NK cell cytotoxicity in in vitro and ex vivo tests using patient samples.
The biotechnology company adds that a ‘surrogate’ induced potent anti-tumor efficacy in vivo in mice in CD20+ tumor models.
Additionally, in ex vivo tests with B-NHL patient samples, IPH6501 was shown to be more effective than a T Cell Engager targeting CD20.
These data were presented on Saturday at the congress of the European Hematology Association (EHA).
In its press release, Innate indicates that IPH6501 thus continues to progress towards a Phase 1 clinical trial.
The biotech also plans to present updated efficacy data from the Phase 2 trial with lacutamab in mycosis fungoides at the ICML congress, which will be held in Lugano, from June 13 to 17.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
